The $59B Quiet Shift Reshaping How Patients Access Care
The $59B Quiet Shift Reshaping How Patients Access Care PR Newswire VANCOUVER, BC, May 12, 2026
MNKD - MannKind Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$8.25
DETAILS
HIGH:
$10.00
LOW:
$6.00
MEDIAN:
$8.50
CONSENSUS:
$8.25
UPSIDE:
144.08%
Stock News
MannKind Corporation (MNKD) Q1 2026 Earnings Call Transcript
MannKind Corporation (MNKD) Q1 2026 Earnings Call Transcript
MannKind: It's Complicated
MannKind Corporation remains a Hold, as revenue growth is increasingly reliant on niche assets like Furoscix and faces margin pressure. United Therapeutics' launch of Tresmi threatens MNKD's Tyvaso DPI royalties, intensifying competitive risks and highlighting MNKD's junior partner status. Pipeline prospects, including MNKD-201 and ralinepag DPI, offer potential but face significant clinical, commercial, and competitive hurdles.
Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics
The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
MannKind (MNKD) Reports Q1 Loss, Misses Revenue Estimates
MannKind (MNKD) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.04 per share a year ago.
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today reported financial results for the first quarter of 2026, and provided a business update.
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ralinepag DPI United Therapeutics plans to be the primary manufacturer of ralinepag DPI MannKind eligible to receive up to $35 million in development milestones plus 10% royalties on net sales DANBURY, Conn.
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ralinepag DPI United Therapeutics plans to be the primary manufacturer of ralinepag DPI MannKind eligible to receive up to $35 million in development milestones plus 10% royalties on net sales DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind to Report First Quarter 2026 Financial Results on May 6, 2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, announced today that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026, after market close.
MannKind Corporation (NASDAQ:MNKD) Short Interest Up 29.8% in March
MannKind Corporation (NASDAQ: MNKD - Get Free Report) saw a large growth in short interest in March. As of March 31st, there was short interest totaling 29,464,200 shares, a growth of 29.8% from the March 15th total of 22,701,389 shares. Approximately 9.8% of the company's stock are short sold. Based on an average daily volume of
MannKind (NASDAQ:MNKD) Shares Gap Up After Insider Buying Activity
MannKind Corporation (NASDAQ: MNKD - Get Free Report) gapped up prior to trading on Wednesday after an insider bought additional shares in the company. The stock had previously closed at $2.61, but opened at $2.81. MannKind shares last traded at $2.7950, with a volume of 2,318,445 shares. Specifically, CEO Michael Castagna bought 100,000 shares of the
MannKind Corporation (MNKD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
MannKind Corporation (MNKD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
Presentations highlight real‑world dosing and titration patterns in youth, and post‑prandial glucose management strategies using inhaled insulin in both adults and youth with T1D Data to be featured across oral and poster sessions at the Advanced Technologies & Treatments for Diabetes Conference (ATTD) PDUFA target action date for Afrezza in children and adolescents living with type 1 or type 2 diabetes set for May 29, 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind Announces Settlement of Convertible Senior Notes
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the settlement of the remaining $36.3 million aggregate principal amount of 2.50% convertible senior notes, all of which were tendered for conversion prior to the maturity date of March 1, 2026. The settlement was made on March 4, 2026, with $35.5 million in cash and 569,023 shares of MannKind common stock.
MannKind to Participate in Upcoming Investor Conferences
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind (NASDAQ:MNKD) Stock Price Down 6.6% on Analyst Downgrade
MannKind Corporation (NASDAQ: MNKD - Get Free Report) traded down 6.6% during mid-day trading on Monday after Wall Street Zen downgraded the stock from a buy rating to a hold rating. The company traded as low as $3.03 and last traded at $3.0650. 1,435,401 shares changed hands during trading, a decline of 72% from the average
Why MannKind Stock Tumbled on Thursday
Investors weren't pleased with the biotech's bottom-line decline. It also missed the consensus analyst estimate for that metric.
MannKind Corporation (MNKD) Q4 2025 Earnings Call Transcript
MannKind Corporation (MNKD) Q4 2025 Earnings Call Transcript
Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for MannKind (MNKD) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
MannKind (MNKD) Reports Q4 Loss, Tops Revenue Estimates
MannKind (MNKD) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.03 per share a year ago.
Price Targets
MannKind price target lowered to $7 from $8 at Mizuho
$7.00
(was $3.56)
Anthony Petrone
·
Mizuho Securities
MannKind price target raised to $10 from $8 at Wells Fargo
$10.00
(was $3.56)
Wells Fargo
MannKind price target raised to $10 from $8 at H.C. Wainwright
$10.00
(was $3.56)
H.C. Wainwright
MannKind price target lowered to $8 from $10 at Mizuho
$8.00
(was $2.58)
Mizuho Securities
MannKind price target lowered to $6 from $7 at Truist
$6.00
(was $2.61)
Truist Financial
MannKind initiated with a Buy at Truist
$9.00
(was $5.03)
Truist Financial
MannKind price target raised to $11 from $9 at H.C. Wainwright
$11.00
(was $5.74)
H.C. Wainwright
MannKind price target raised to $8 from $7 at RBC Capital
$8.00
(was $4.00)
Douglas Miehm
·
RBC Capital
H.C. Wainwright positive on MannKind deal for scPharmaceuticals
$9.00
(was $3.90)
H.C. Wainwright
MannKind price target raised to $12 from $10 at Oppenheimer
$12.00
(was $5.38)
Steven Lichtman
·
Oppenheimer
MannKind Analyst Turns Bullish, Says 'Don't Call It Comeback'
$10.00
(was $4.23)
Andreas Argyrides
·
Wedbush